Research graph
References from Carfilzomib plus induction chemotherapy for children with relapsed or refractory acute lymphoblastic leukemia. Local targets link to admitted publications; unresolved targets remain external evidence.
Childhood and adolescent cancer statistics, 2014
2014 · External reference
Childhood acute lymphoblastic leukemia: progress through collaboration
10.1200/jco.2014.59.1636 · 2015 · External reference
Determinants of survival after first relapse of acute lymphoblastic leukemia: a Children's Oncology Group study
10.1038/s41375-024-02395-4 · 2024 · External reference
Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study
10.1038/s41375-018-0094-0 · 2018 · External reference
Updates in the management of relapsed and refractory acute lymphoblastic leukemia: an urgent plea for new treatments is being answered
10.1200/op.21.00843 · 2022 · External reference
Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis
10.1182/bloodadvances.2021005579 · 2022 · External reference
Phase II trial of inotuzumab ozogamicin in children and adolescents with relapsed or refractory B-cell acute lymphoblastic leukemia: Children's Oncology Group Protocol AALL1621
10.1200/jco.21.01693 · 2022 · External reference
Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study
10.1038/s41417-021-00418-1 · 2022 · External reference
Daratumumab in pediatric relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS study
10.1182/blood.2024024493 · 2024 · External reference
Fratricide-resistant CD7-CAR T cells in T-ALL
10.1038/s41591-024-03228-8 · 2024 · External reference
Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia
10.1056/nejmoa2300709 · 2023 · External reference
Optimal approach to T-cell ALL
10.1182/hematology.2022000337 · 2022 · External reference
How I treat postimmunotherapy relapsed B-ALL
10.1182/blood.2024024517 · 2025 · External reference
The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood
10.1111/bjh.14505 · 2017 · External reference
Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children's Oncology Group
10.1111/bjh.15919 · 2019 · External reference
Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia
10.1056/nejmoa1609783 · 2017 · External reference
Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study
10.1200/jco.2009.22.2950 · 2010 · External reference
Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia
10.1038/leu.2013.366 · 2014 · External reference
Activity of immunoproteasome inhibitor ONX-0914 in acute lymphoblastic leukemia expressing MLL-AF4 fusion protein
10.1038/s41598-021-90451-9 · 2021 · External reference
Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium
10.1002/pbc.22456 · 2010 · External reference
Unresolved reference
2022 · External reference
Carfilzomib: a promising proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma
10.3389/fonc.2021.740796 · 2021 · External reference
Anti-leukemic activity of bortezomib and carfilzomib on B-cell precursor ALL cell lines
10.1371/journal.pone.0188680 · 2017 · External reference
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma
10.1182/blood-2007-01-065888 · 2007 · External reference
Phase 1b study of carfilzomib with induction chemotherapy in pediatric relapsed/refractory acute lymphoblastic leukemia
10.1002/pbc.29999 · 2022 · External reference
The complete story of less than complete responses: the evolution and application of acute myeloid leukemia clinical responses
10.1016/j.blre.2021.100806 · 2021 · External reference
Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies
10.1002/sim.6607 · 2015 · External reference
10.1007/978-3-031-97281-2_13
10.1007/978-3-031-97281-2_13 · 2025 · External reference
Unresolved reference
2023 · External reference
Phase I/phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
10.1200/jco.2016.67.3301 · 2016 · External reference
FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma
10.1634/theoncologist.2006-0017 · 2008 · External reference
Venetoclax combined with chemotherapy in pediatric and adolescent/young adult patients with relapsed/refractory acute lymphoblastic leukemia
10.1002/pbc.31630 · 2025 · External reference
